Caspase 8/10-associated RING proteins (CARPs) are a recently described family of protein ubiquitin ligases that interact with and negatively regulate death receptor-mediated apoptosis. Because CARPs are overexpressed in cancer and their silencing reduces cell viability and sensitizes tumor cells to chemotherapeutic agents, we investigated their relationship to p53 tumor suppressor signaling. p53 is a major determinant of chemosensitivity, and its levels are increased following DNA damage through N-terminal phosphorylation and inhibition of degradation. Although p53 is well known to be negatively regulated by several ubiquitin ligases including MDM2, none are known to target phosphorylated p53 for degradation. CARPs physically interact with and ubiquitinate p53, targeting it for degradation in the absence of MDM2. Serine 20-phosphorylated p53 is also ubiquitinated by CARPs. CARP silencing stimulates p53 expression and promotes downstream effects, including transcriptional activation and tumor suppression.
1/2 are a recently characterized protein family with a ubiquitin protein ligase encoded in their RING domain (1) . CARP1 and CARP2 distinctively target apical death effector domain-containing caspases 8 and 10, but not 9, and are cleaved by active caspases 8 and 10 once the extrinsic cell death pathway is initiated and transduces a death signal (1) . The CARP proteins share three highly conserved functional domains, FYVE (Fab1p, YOTB, Vac1P, and EEA1) (2) , CID (Caspase-Interacting Domain), and RING (Really Interesting New Gene) (3) (Fig.   1a) . A point mutation of a catalytically essential histidine to an alanine in the RING finger domain abolishes CARP1 (His-342) or CARP2 (His-333) E3 ligase activity (1) (Fig. 1a) . The cysteine and histidine residues in the CARP RING domains completely align with the RING consensus sequence (4) . The characteristic residues of RING domains are conserved in both CARP1 and CARP2 and to a large extent with the RING domains of MDM2 (5), c-Cbl (6) , and tumor necrosis factor-R-associated factor 2 (7) . CARP proteins, especially the functional domains, are also markedly conserved across different organisms from human, mouse, and frog to Drosophila (1) . Despite their many similarities, we show here that CARP1 and CARP2 are also functionally distinct.
Compared with the canonical IAPs (Inhibitor of Apoptosis Protein), which contain BIR (Baculovirus IAP Repeat), CARD (Caspase Activation and Recruitment Domain), and RING motifs and inhibit caspases 3, 7, and 9, CARPs represent a new family of apoptosis inhibitors specifically targeting death effector domain-containing caspases for degradation. In the cascade of the apical cell death pathway, how CARPs are involved in the regulation of caspases 8 and 10 remains elusive. One possible role for CARPs may be in purging excess pro-caspases 8 and 10 that could otherwise be activated to cause cell death, because CARPs do not appear to control active caspases (1) .
Because CARP silencing by RNA interference significantly sensitizes cells to chemotherapy-induced apoptosis and inhibits cancer cell colony formation (1), we hypothesized that CARPs may be involved in regulation of p53. Chemotherapeutic agents cause DNA damage, which in turn stabilizes p53 via its well known post-translational modifications (8) . The basal level of p53 is maintained at very low levels due to the tight regulation of p53 by the E3 ligase MDM2 (9) . Other negative regulators of p53 that rely on RING domains include COP1 (10), Topors (11), ICP0 (12), Pirh2 (13) , and E6/E6-AP (14) . Because CARP silencing sensitizes cells to DNA damage, we hypothesized that CARPs may regulate tumor-suppressive events downstream of p53. Because CARPs act as E3 ligases to degrade caspases 8 and 10, we tested the ability of CARPs to degrade p53 protein. We observed that upon the knock down of gene expression of CARPs, p53 level becomes elevated, resulting in cell cycle arrest and apoptosis. Because CARPs act as ubiquitin protein ligases that target caspases 8/10, we speculated that CARPs could serve as E3 ligases to degrade p53 in a proteasome-mediated manner. Our results support this hypothesis and further identify a novel association between CARPs and p53 phosphorylated on N-terminal serines. Unlike MDM2 or other E3 ligases known to target p53, CARP1 and CARP2 appear to target phosphorylated p53 for ubiquitination and degradation. As such, CARP1 and CARP2 that are overexpressed in cancer may have oncogenic activity capable of eliminating stress-induced p53 protein that is normally refractory to MDM2-dependent proteolytic degradation.
EXPERIMENTAL PROCEDURES
Cell Lines, Antibodies, and Reagents-Cell lines included in the present study were cultured in Dulbecco's modified Eagle's medium (HeLa, SW480, MEF (p53/MDM2 Ϫ/Ϫ , a generous gift from Dr. Stephen N. Jones, University of Massachusetts), Saos2, and 293), McCoy's 5A medium (HCT116, HCT116 (p53 Ϫ/Ϫ ), and U2OS), or RPMI1640 (H460 and H460-E6). Antibodies were purchased from Sigma (FLAG, FLAG-agarose and FLAGhorseradish peroxidase), Santa Cruz (GFP, p53-Fl-393, and DO1), R&D Systems (p53-Ser-15/20 and MDM2), Cell Signaling (p53-Ser-20), Calbiochem (p21-Ab-1), Roche Applied Science (anti-HA), BD Transduction Laboratories (Ran) and generated in the Cell Center at the University of Pennsylvania (CARP2 monoclonal antibody, 3A7B9). Proteasome inhibitors were chosen from Calbiochem (MG-132, lactacystin, and epoxomicin). Doses of chemotherapeutic agents were as follows: adriamycin (0.2 g/ml), CPT11 (50 M), etoposide (50 M), and 5-fluorouracil (0.3 mM). Cycloheximide was used at 50 g/ml. Doses of proteasome inhibitors were: MG-132 (10 M), lactacystin (5 M), and epoxomicin (0.5 M).
Plasmids and Adenoviruses-CARPs and mutants were constructed in vector pFLAG-CMV2 (Sigma) as described (1) . Ad/His-MDM2 was constructed by a previously described method (20) . MDM2 cDNA was obtained by reverse transcription PCR from H460 cells and verified by sequencing. The open reading frame was inserted to pcDNA4/HisMax vector (Invitrogen) at the EcoRI and BamHI restriction sites to obtain a His 6 -tagged MDM2 cDNA. The fragment partially digested by HindIII and EcoRV from the plasmid pcDNA4/ HisMax/MDM2, containing the QBI SP163 translational enhancer, polyhistidine (His 6 ), and in-frame MDM2, was inserted into the pAdTrack-CMV vector at the corresponding sites. The pAdTrack-CMV/MDM2 construct was recombined with pAdEasy-1 (a generous gift from Bert Vogelstein) in Escherichia coli BJ5183 cells to get recombined pAD with the exogenous insert. The recombined adenovirus was replicated and amplified in 293 cells by transfection of the pAD plasmid DNA. The amplified viruses were purified by cesium chloride gradient ultracentrifugation and stored at Ϫ80°C in a buffer containing 25% (v/v) glycerol, 10 mM Tris, pH 8.0, 100 mM NaCl, 0.1% bovine serum albumin, and 1 mM MgCl 2 . Ad-CARP1 or Ad-FLAG-CARP2 were made accordingly. Briefly, the full length of CARP1 or FLAG-tagged CARP2 coding sequence was cloned into the pAdTrack-CMV vector at the HindIII or KpnI site; after recombination screening, the recombinant plasmid pAD with the exogenous insert was obtained and then replicated and amplified in 293 cells before cesium gradient purification.
Overexpression of CARPs and Other Proteins-Mammalian expression vectors were transiently transfected into human or mouse cells growing in 6-well plates or 10-cm dishes using Lipofectamine and Plus reagent (Invitrogen). At 24 h after transfection, cells were treated with chemotherapeutic agents for another 20 h or with proteasome inhibitor (MG-132, 10 M) for 8 -12 h or harvested without further treatments in 1ϫ Laemmli sample buffer or co-immunoprecipitation buffer (30 mM Tris, pH 7.5, 150 mM NaCl, 10% glycerol, and 1% Triton X-100 with 1ϫ complete protease inhibitor plus 1 mM phenylmethylsulfonyl fluoride).
Coimmunoprecipitation-Treated cells in plates or dishes were washed three times on ice with PBS, and then coimmunoprecipitation buffer was added and cell lysates were collected. Phenylmethylsulfonyl fluoride was freshly added to each sample at a final concentration of 1 mM, and cell lysates were rotated at 4°C for 1 h. Lysates were cleared for 15 min at top speed in a microcentrifuge at 4°C. The supernatant was precleared with mouse IgG-agarose or rabbit IgG-agarose (Sigma) for 1 h, followed by overnight immunoprecipitation with specific antibodies at 4°C, and then immune complexes were precipitated with r-Protein G-agarose (Invitrogen).
Ubiquitination of p53-Cells were transfected with the indicated plasmids in 6-well plates and grown overnight. Eight hours before harvesting cells, the proteasome inhibitor MG-132 was added to the growth medium. Cells were rinsed twice with Tris-buffered saline (TBS, 154 mM NaCl and 100 mM Tris, pH 7.5) and then lysed in the denaturing buffer (TBS, 1 mM EDTA and 1% SDS, pH 7.5). Cell lysates were denatured by heating at 100°C for 10 min before being 10-fold diluted with co-immunoprecipitation buffer. The proper anti-p53 antibody (DO-1 or anti-phospho-p53-Ser-20) was added to the diluted cell lysates. The p53-antibody complex was allowed to form overnight and captured with protein A-agarose. The ubiquitinated p53 was assessed accordingly.
Immunofluorescence of CARP2 and p53-Cells were transfected with the appropriate plasmids in 6-well plates and incubated overnight. Cells were then trypsinized and replated into 8-well chamber slides (Lab-Tek) and allowed to attach overnight. Cells were fixed with 3% paraformaldehyde in PBS ϩ 1 mM MgCl 2 for 5 min, washed with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 10 min. Cells were blocked for 1 h at room temperature in 20% donkey serum (Sigma) in PBS-TB (PBS with 0.2% Triton X-100 and 0.1% bovine serum albumin). After washing the cells in PBS-TB, they were incubated for 2 h with primary antibody that was diluted in PBS-TB. Anti-FLAG (M2; Sigma) was diluted by 1:1000, and anti-p53 (FL-393; Santa Cruz Biotechnology) was diluted by 1:2000. After washing the cells thoroughly in PBS-TB, the slides were incubated in either donkey anti-mouse-Cy3 or donkey anti-rabbit-Cy2 secondary antibodies (Jackson Immunoresearch) at a 1:600 dilution for 1 h. The cells were washed with PBS-TB and then water and incubated for 1 min in a 1:50 K dilution of Hoechst 33258 (10 mg/ml; Molecular Probes) to visualize the nuclei.
In Vitro Imaging Analysis-At 20 h after cells were transfected in 6-well plates with PG13-Luc and pRL-TK, the cells were replated into 96-well black plates (Fisher Scientific) and maintained for 1 h at 37°C in an incubator supplemented with 5% CO 2 and 100% humidity before the substrates, D-luciferin (150 g/ml as a substrate of firefly luciferase; Biotium) and native coelenterazine (10 g/ml as a substrate of Renilla luciferase; Biotium) were added to different duplicate wells receiving the same treatment. The bioluminescence image was acquired using a cooled charge-coupled device camera in an in vivo imaging system (IVIS; Xenogen). The Renilla luciferase activity was used to normalize the readout for the firefly luciferase activity.
Colony Formation Studies-Cells from several cell lines were treated with pSuper-puro-C1-424 and pSuper-puro-C2-861 as previously described (1) . At 24 h after transfection, cells were maintained in puromycin-containing medium (1.5 g/ml) for 3 days, followed by serial dilution plating in 6-well plates. Colony formation was analyzed after 2-4 weeks by Coomassie Blue staining.
RESULTS AND DISCUSSION
To investigate whether CARPs interact with p53, wild-type (WT) CARP1 (C1), CARP2 (C2), RING domain-mutated CARP1-H342A (C1-342), or CARP2-H333A (C2-333) were exogenously co-expressed with p53 in H460 or HCT116 human tumor cells. Co-immunoprecipitation of p53 and CARPs was observed with WT CARP proteins, and this interaction was enhanced with mutated (mt) CARPs (Fig. 1b) . In HCT116 cells, p53 co-immunoprecipitated with CARPs using the FLAG antibody (Fig. 1c) ; however, only an interaction of p53 with mt CARPs was observed when the lysates were immunoprecipitated with a p53 antibody. The proteasome inhibitor MG-132 stabilized and allowed the visualization of the interaction between WT CARP and p53 when the lysates were immunoprecipitated with a p53 antibody (Fig. 1d) . The need to use a proteasome inhibitor to observe significant association between WT CARPs and p53 suggests that WT CARPs interact with p53 only transiently and this interaction may involve the E3 ligase activity. Because loss of E3 ligase activity enhances binding of CARPs to p53, this strongly suggests that stabilization of p53 that is a target of the E3 ligase activity of CARPs allows more easy detection of the complex. An endogenous interaction between the CARPs and p53 was examined using antibodies that we generated against CARP2. Endogenous p53 induced by adriamycin was immunoprecipitated with anti-p53 (full-393), and endogenous CARP2 was detected by immunoblotting with anti-CARP2 monoclonal antibody. CARP2, but not IgG, co-immunoprecipitated with p53, demonstrating that endogenous CARP2 interacts with endogenous p53 (Fig. 1e) .
Because MDM2 is a major regulator and interacting protein of p53, the effect of MDM2 on the interaction of CARPs and p53 was examined. p53 Ϫ/Ϫ ,MDM2 Ϫ/Ϫ mouse embryo fibroblast (MEF) cells were co-transfected with p53 and C1, C2, C1-342, or C2-333, and cell extracts were immunoprecipitated with anti-FLAG (m2) and immunoblotted with anti-p53 (Fig. 1f) . Transfected p53 co-immunoprecipitated more with mt CARPs, as compared with WT CARPs, consistent with what was observed for overexpressed proteins in H460 cells (Fig. 1b) . These results indicate that CARPs can interact with p53 independently of MDM2.
To map the domain on CARPs implicated in binding with p53, several deletion mutants of CARPs were generated and tested in co-immunoprecipitation experiments. The mutants included CARP1 C terminus (C1-C), CARP1 N terminus (C1-N), CARP1 with RING domain deletion (C1-⌬RING), CARP1 with deletion of the first 115 amino acid residues in the N terminus (C1-⌬1-115), and CARP2 with RING domain deletion (C2-⌬RING) in addition to C1 and C2 (all FLAG tagged, Fig.  1g ). Overexpressed C1, C1 mutants, C2, and C2 mutants interacted efficiently with p53 with the exception of C1-⌬RING and C1-N, and especially C2-⌬RING. It is clear that C1-⌬RING binds less well to p53 than full-length CARP1, whereas in the case of the C2-⌬RING there is no detectable interaction with p53. These results suggest that the RING domain on CARP1 is at least partially involved in the binding of CARP1 to p53 whereas the RING domain of CARP2 appears to be essential for interaction of CARP2 with p53. (Fig. 1h) . The RING domain functions as a molecular scaffold to bring together the E2 and substrates to enhance ubiquitylation (15) . Therefore, binding of p53 to the RING domain of CARPs may be necessary in regulation of p53 degradation. Exogenously expressed CARP2 colocalized with p53 in the cytoplasm and in the nucleus (Fig. 1i) .
As a potent tumor suppressor, p53 is highly mutated in a variety of cancers (16) and inactivated in most other cancers (8) . Because other RING domain-containing proteins such as MDM2 (9), Pirh2 (13), and COP1 (10) are p53-interacting proteins that down-regulate p53, we examined the possibility that CARPs might also negatively regulate p53. Overexpressed C1 and C2, but not C1-342 or C2-333, degraded exogenously expressed p53 in a series of p53-null cells including p53
Ϫ/Ϫ MEFs (Fig. 2a) , p53 Ϫ/Ϫ HCT116, or Saos-2 cells in a WT CARP dose-dependent manner (Fig. 2b) . Wild-type CARPs, rather than RING domain point mutants, also decreased the steady-state levels of endogenous p53 in U2OS in a WT CARP dose-dependent fashion (Fig. 2c) . In Fig. 1, b, c, and f, the lack of an observed difference in the decrease in p53 protein levels between WT and mt CARPs was probably due to overexpression of p53 in order to increase co-immunoprecipitation efficiency, and likely saturation of the proteasome (17) .
To gain further insight into the mechanism of CARP-mediated reduction of p53 protein levels in cells, overexpressed CARP1 and CARP2 reduced endogenous p53 levels in cycloheximide-treated H460 cells. Thus CARP expression led to a reduction in the stability of p53, showing that CARPs actively facilitate the turnover of p53 protein (Fig. 2d) . Moreover, knock down of endogenous CARP2 markedly prolonged the stability of the endogenous p53 protein in cycloheximide-treated PA-1 cells (Fig. 2e) . Knock down of C1 and C2 also led to a significant increase in adriamycin-or etoposide-induced p53 levels (Fig.  2f ) . These data suggest that CARPs down-regulate p53 by interacting with and then potentially targeting p53 for degradation.
Given that CARP levels are negatively correlated with p53 protein levels, independent of MDM2 (Fig. 2a) , it is possible that CARPs induce p53 degradation through a post-translational mechanism. To test this hypothesis, several cell lines were used to examine CARP-mediated changes in exogenous or endogenous p53 protein levels. p53 Ϫ/Ϫ ,MDM2 Ϫ/Ϫ MEFs were transfected with C1, or C2, or C1-⌬RING, or C2-⌬RING and treated with the proteasome inhibitor MG-132 (Fig. 3a) .
The addition of the proteasome inhibitor was found to considerably increase the level of p53 protein, which was previously reduced by the transfection of C1 or C2. In addition, the proteasome inhibitor elevated the level of endogenous p53 protein reduced otherwise by exogenously expressed C1 or C2 in H460 cells (Fig. 3b) . The inhibitors epoxomicin and lactacystin enhanced the level of 5-fluorouracil-induced p53 protein otherwise degraded by exogenously expressed C1 or C2 in HCT116 cells (Fig. 3c) . The enhanced binding capability of the CARP RING domain mutants to p53 as compared with the full-length CARP proteins (Fig. 1, b and f ) suggested that the intact RING domains might confer upon C1 or C2 an E3 ubiquitin ligase activity with p53 as a potential substrate. To verify the involvement of proteasome-mediated degradation of p53 by CARPs, MG-132 was applied and interaction between CARPs and p53 was tested. Inhibition of the 26 S proteasome increased the amount of p53 protein bound to C1 or C2 as compared with controls without MG-132 in HeLa cells (Fig. 3d) . This enhancement was not observed in C1-342 or C2-333 in H460 cells (Fig.  3e) . These data indicate that CARPs direct p53 degradation through the proteasomal pathway. In Fig. 3e, MG132 had a marginal effect on p53 levels in whole cell extracts, probably due to overexpression of p53 in order to increase co-immunoprecipitation of p53, and saturation of the proteasome (17) . To ascertain whether CARP-mediated degradation of p53 by the proteasome is a direct consequence of p53 ubiquitination, p53-null HCT116 cells were transfected with p53, HA-ubiquitin, WT CARPs, or RING domain-mutated CARPs (Fig. 3f ) . In addition, wild-type p53-expressing H460 and HCT116 cells were transfected with HA-ubiquitin, WT CARPs, or RING domain-mutated CARPs (Fig. 3g) . Immunoprecipitation with anti-p53 under denaturing conditions and immunoblotting with anti-HA revealed that co-transfection of WT, but not mt CARPs, targets p53 ubiquitination via the proteasome for deg- Ϫ/Ϫ ) cells were transfected with CARPs (WT or mt) and p53, and then the levels of p53 were assessed by immunoblotting. b, CARPs reduce the level of exogenous p53 in a dose-dependent manner. Increasing amounts of CARPs (WT or mt) with a constant amount of p53 were transfected into HCT116 (p53 Ϫ/Ϫ ) or Saos-2 (p53-null), and the levels of p53, CARPs, and Ran proteins were assessed by immunoblotting. c, CARPs down-regulate levels of endogenous p53 in a dose-dependent manner. Increasing amounts of CARP (WT or mt)-expressing adenovirus were infected into U2OS cells, and levels of endogenous p53, Ran, and infected CARP proteins were assessed by immunoblotting. The efficiency of expressed CARP1 without FLAG tags was reflected by co-expressed GFP from the same adenovirus expression vectors. d, CARPs reduce the half-life of endogenous p53. H460 cells were transfected with CARPs and treated with the translation inhibitor cycloheximide for the indicated times, and levels of endogenous p53 at the different time points were assessed by immunoblotting. e, PA-1 cells were depleted of CARP2 with RNA interference and treated with the translation inhibitor cycloheximide for the indicated times, and levels of endogenous p53 at the different time points were assessed by immunoblotting. The relative p53 expression levels over time are graphically indicated. Retro refers to empty retroviral vector control, and C2-861 refers to CARP2 shRNA. f, knock down of CARPs by RNA interference increases chemo-induced levels of p53. H460 cells were transfected with plasmids producing CARP1 or CARP2 shRNA to deplete endogenous CARP1 or CARP2, followed by the addition of chemotherapeutic agents (as indicated), and endogenous p53 levels in lysates were detected by immunoblotting.
radation. In Fig. 3f , reblotted polyubiquitin p53 ladders were induced only by WT CARPs, but not mt CARPs, further confirming that CARP targets the ubiquitination of p53. These data demonstrate that CARPs act as E3 ligases for p53.
It is clear that CARPs target p53 for degradation through the proteasomal pathway, independent of MDM2. Because MDM2 is not able to degrade p53 phosphorylated at serine 20 (phospho-p53 ser20 ), to distinguish the ability of CARPs from MDM2 to possibly down-regulate phospho-p53 the interaction between CARPs and phospho-p53 at Ser-20 was investigated. SW480 cells expressing stable endogenous mutant p53 were transfected with FLAG-tagged C1, C1-342, C2, or C2-333, followed by the addition of adriamycin for 20 h, immunoprecipitation with anti-FLAG, and immunoblotting with anti-phospho-p53 ser20 (Fig. 4a) . More phospho-p53 was immunoprecipitated in the presence of transfected C1-342 or C2-333 as compared with C1 or C2, reminiscent of the preferential immunoprecipitation of transfected p53 by CARP mutants (Fig. 1, b and f ) .
To investigate the possibility that CARPs mediate ubiquitination of phospho-p53 ser20 , wild-type p53-expressing HCT116 cells were transfected with HA-ubiquitin, and C1, or C1342, or C2, or C2-333, followed by adriamycin-induced p53 phosphorylation, immunoprecipitation under denaturing conditions with anti-phospho-p53 ser20 , and immunoblotting with anti-HA (Fig.  4b) . Phospho-p53 ser20 was ubiquitinated only in the presence of C1 or C2, not C1-342 or C2-333, indicating that CARPs target phosphop53 ser20 for degradation via the proteasome by ubiquitination, rather than by dephosphorylation. Neither RING nor HECT (3) type E3 ligase has been previously demonstrated to recognize and ubiquitinate phospho-p53 for degradation, including MDM2, COP1, Pirh2, or E6/E6-AP. To determine the effect of CARP overexpression on degradation of phospho-p53 ser20 , H460 cells were infected with adenovirus expressing GFP, CARP1, CARP2, or MDM2 treated with CPT11 and immunoblotted with anti-phospho-p53 ser20 (Fig.  4c) . Not only were p53 levels in whole cell extracts significantly affected by CARP expression but overexpression of CARPs also markedly reduced the level of phospho-p53 ser20 , whereas MDM2 stabilized phospho-p53 ser20 , presumably due to degradation of endogenous CARP2 by overexpressed MDM2. 3 To further verify the notion that CARP targets phospho-p53 ser20 for degradation rather than dephosphorylation, U2OS cells were infected and CPT-11 treated, followed by Me 2 SO or proteasome inhibitor MG-132 administration before immunoblotting with antiphospho-p53 ser20 (Fig. 4c) . MG-132 stabilized the level of phosphop53 ser20 , which is otherwise degraded by overexpressed CARP protein, again indicating that CARPs degrade phospho-p53 ser20 through a proteasome-mediated pathway rather than dephosphorylation. To further support the notion of CARP-dependent downregulation of phospho-p53 at serine 20, H460 cells and the indicated adenoviruses were used. In the last 12 h, cycloheximide was administered at indicated time points to inhibit cellular protein translation. Wild-type CARPs, rather than control and MDM2, significantly facilitated the degradation of phospho-p53 ser20 (Fig.  4d) . To assess the ability of endogenous CARPs to negatively regulate phospho-p53 ser20 in a chemo-induced setting, five different human cancer cell lines expressing wildtype p53 protein were treated with adriamycin for 20 h before immunoblotting with anti-phosphop53 ser20 or anti-CARP2 (Fig. 4e) . PA-1 cells with the lowest level of CARP2 proteins revealed the highest level of phospho-p53 ser20 . U2OS, MCF7, and HCT116 cells showed relatively higher levels of CARP2 as compared with PA1 and their phospho-p53 ser20 levels were low. H460 cells with the highest level of CARP2 proteins showed lower levels of phospho-p53 ser20 as compared with PA1 cells. PA-1 and H460 cells plated at the same density were treated with adriamycin for 20 h followed by drug-free growth for 24 h and were stained with Coomassie Blue (Fig. 4e) . PA-1 cells were more sensitive to adriamycin than H460 cells, consistent with the possibility that CARPs might serve to control 3 W. Yang and W. S. El-Deiry, unpublished observations. FIGURE 4. CARPs negatively regulate phospho-p53 ser20 . a, CARPs interact with phospho-p53 at serine 20. SW480 cells were transfected and treated with adriamycin for 20 h, followed by immunoprecipitation with anti-FLAG and immunoblotting with anti-phospho-p53 ser20 . b, CARPs mediate ubiquitination of phosphop53 ser20 . HCT116 cells were transfected with WT or mt CARPs and HA-ubiquitin and then treated with adriamycin for another 20 h, followed by MG-132 in the last 8 h. Immunoprecipitation under denaturing conditions and immunoblotting were performed as indicated. c, H460 cells were infected with various advenoviruses (as indicated) for 12 h followed by CPT11 treatment for 20 h, and endogenous levels of phospho-p53 ser20 and other proteins were detected by immunoblotting. U2OS cells were infected with the indicated adenoviruses for 12 h followed by CPT11 treatment for another 6 h, and then cells were treated with Me 2 SO or MG132 before endogenous levels of phospho-p53 ser20 were determined by immunoblotting. d, CARPs reduce the half-life of endogenous phospho-p53 ser20 . H460 cells were treated with CPT11 for 20 h followed by infection of various advenoviruses (as indicated) for 36 h before being treated with the translation inhibitor cycloheximide for the indicated times. Subsequently, levels of endogenous phospho-p53 ser20 at the different time points were assessed by immunoblotting. e, correlation of levels of CARP2 and phospho-p53. Five different tumor cell lines with wild-type p53 were treated with adriamycin for 24 h and then endogenous CARP2 and phospho-p53 ser20 levels were assessed by immunoblotting. PA-1 and H460 cells at the same density were treated with adriamycin for 20 h, followed by an additional 24-h culture in drug-free medium before attached cells were stained with Coomassie Blue.
